Innovheart Raises $55 Million In Series C Financing To Further Develop The Trans-Septal Saturn Transcatheter Mitral Valve Replacement System
Innovheart Raises $55 Million In Series C Financing To Further Develop The Trans-Septal Saturn Transcatheter Mitral Valve Replacement System
01/27/22, 8:00 AM
Location
milanMoney raised
$55 million
Round Type
series c
InnovHeart s.r.l., a developer of novel Transcatheter Mitral Valve Replacement (TMVR) systems for the treatment of mitral valve disease, announces the closing of its Series C financing with granting an exclusive licensing agreement to Grand Pharmaceutical Group Limited, (Grand Pharma) for its proprietary Saturn device in Greater China. The transaction pulled in more than $55 million in equity, upfront licensing fees, milestone payments and structured royalties.
Company Info
Location
milan, lombardy, italy
Additional Info
InnovHeart s.r.l, with locations in Milan, Italy, and Newton, Mass., USA, develops Transcatheter Mitral Valve Replacement systems (TMVR) to treat patients suffering from mitral valve disease. The company is conducting clinical trials of its novel Saturn TMVR system. Saturn is a low-profile mitral heart valve designed for trans-apical or trans-septal delivery.